Evaluation of Lung Function Using Xenon Gas with CT Imaging in Lung and Breast Cancer Patients Receiving Radiotherapy

4 1 1

What is this study about?

This study looks at lung cancer and breast cancer in people who are receiving radiotherapy, which is a treatment that uses high-energy rays to destroy cancer cells. Radiotherapy can sometimes cause changes or damage to the lung tissue, leading to conditions such as radiation pneumonitis, which is inflammation of the lungs, or radiation fibrosis, which is scarring of the lung tissue. The study will use a special gas mixture called Messer mixture 30 Vol% Xe in 70 Vol% O2, which contains xenon and oxygen. This gas mixture will be breathed in by participants and acts as a contrast agent, meaning it helps create clearer images during scanning. The scanning method used is called Dual-Energy CT-imaging, which is a type of computed tomography scan that can show both the structure of the lungs and how well they are working.

The purpose of this study is to collect detailed information about lung structure and function before and after radiotherapy treatment. By comparing images taken before treatment starts with images taken after treatment is completed, researchers want to see what changes happen in the lungs as a result of the radiotherapy. These changes will be looked at by examining ventilation maps, which are special images that show how air moves through different parts of the lungs. The study aims to identify areas where the lung function may have improved or worsened due to the radiation treatment.

During the study, participants will undergo scanning sessions where they will breathe in the xenon and oxygen gas mixture while lying in the CT scanner. The scans will capture images of the lungs while the gas is present, allowing doctors to see which areas of the lungs are receiving good airflow and which areas may not be working as well. Participants will need to hold their breath for short periods of about three seconds during the scanning. The study will involve scans done before the radiotherapy begins and again after the radiotherapy treatment has finished, so that doctors can measure and compare any changes that have occurred in lung function and tissue structure.

1 Initial imaging scan before treatment

Before starting radiation therapy, a special imaging scan will be performed to assess lung function.

This scan uses a technique called Dual-Energy CT imaging, which is an advanced type of computed tomography scan that takes detailed pictures of the lungs.

During the scan, a gas mixture will be inhaled to help visualize how air moves through the lungs. This gas mixture contains 30% xenon and 70% oxygen.

The gas is administered through inhalation, meaning it will be breathed in during the scan.

The scan requires holding breath for 3 seconds to capture clear images.

This initial scan creates a baseline map of lung ventilation, showing how air flows through different areas of the lungs before any treatment begins.

2 Radiation therapy treatment period

After the initial imaging scan, radiation therapy treatment will be administered as planned by the treating physician.

The radiation therapy is the standard treatment for lung or breast cancer and is not modified by participation in this imaging study.

During this period, no additional imaging scans with the xenon gas mixture are performed.

3 Follow-up imaging scan after treatment

After completing radiation therapy, a second imaging scan will be performed using the same method as the initial scan.

The same gas mixture of 30% xenon and 70% oxygen will be inhaled during this scan.

The scan again requires holding breath for 3 seconds.

This follow-up scan creates a second ventilation map of the lungs, showing how air flows through the lungs after radiation therapy.

The purpose of this second scan is to compare lung function before and after treatment, allowing assessment of any changes in the lung tissue caused by radiation therapy.

The comparison between the two scans will show any areas where ventilation patterns have changed, which may appear as different colored areas on the lung maps.

Who Can Join the Study?

  • You must have lung cancer or breast cancer with a TNM classification of I-IIIa, which is a system doctors use to describe the size of the tumor and whether the cancer has spread to nearby areas or lymph nodes
  • You must be between 50 and 80 years old
  • You must not have received any prior cancer treatment, meaning you have not had chemotherapy, radiation therapy, or surgery for cancer before
  • You must be able to hold your breath for 3 seconds
  • You must be in stable condition, meaning your health is not rapidly changing or worsening, and you are not currently staying in an ICU, which is an intensive care unit for very seriously ill patients
  • You must not have COPD GOLD IV, which is the most severe stage of chronic obstructive pulmonary disease, a serious lung condition that makes breathing very difficult
  • You must sign an informed consent form, which is a document showing you understand the study and agree to participate

Who Cannot Join the Study?

  • The study does not list specific exclusion criteria, which are conditions or situations that would prevent someone from participating in the clinical trial
  • You should discuss with the research team whether you are suitable for this study based on your individual health situation
  • General safety considerations for this type of imaging study may apply, such as allergies to contrast agents (special substances used to make images clearer) or inability to lie still during scanning
  • Women who are pregnant (expecting a baby) or breastfeeding (nursing a baby) may not be able to participate due to radiation exposure
  • People with severe breathing problems may not be able to safely breathe the gas mixture containing xenon (a special gas used for imaging) and oxygen

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Vrije Universiteit Brussel Jette Belgium

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not yet recruiting
01.01.2026

Trial locations

Investigated drugs:

Xenon gas mixture is a breathable gas used as a contrast agent during special CT scans to help doctors see how well your lungs are working. In this study, you will breathe in a mixture that contains 30% xenon gas combined with 70% oxygen. This gas mixture is safe to breathe and helps create detailed images that show which parts of your lungs are ventilating properly. The images help doctors understand how radiation therapy affects your lung tissue.

Radiation Pneumonitis – Radiation pneumonitis is an inflammation of the lungs that occurs as a side effect of radiation therapy to the chest area. This condition typically develops within weeks to months after receiving radiation treatment for cancers such as lung or breast cancer. The lung tissue becomes inflamed and swollen in the areas that were exposed to radiation. Patients may experience symptoms such as shortness of breath, cough, and chest discomfort. The condition can affect the normal functioning of the lungs and reduce their ability to exchange oxygen efficiently. In some cases, the inflammation may resolve on its own, while in others it can progress to more persistent changes in the lung tissue.

Radiation-Induced Pulmonary Fibrosis – Radiation-induced pulmonary fibrosis is a condition where lung tissue becomes scarred and stiff following radiation therapy to the chest. This typically develops months to years after the completion of radiation treatment. The radiation causes permanent damage to the lung tissue, leading to the formation of fibrous scar tissue that replaces normal, healthy lung tissue. As the fibrosis progresses, the lungs lose their elasticity and ability to expand properly during breathing. This results in reduced lung capacity and difficulty breathing, particularly during physical activity. The scarring process is generally irreversible and represents a chronic change in the lung structure.

Lung Cancer – Lung cancer is a disease in which abnormal cells grow uncontrollably in one or both lungs, forming tumors that interfere with normal lung function. These cancerous cells typically start in the lining of the airways or in the air sacs of the lungs. As the cancer grows, it can block airways, cause fluid buildup, and prevent the lungs from working properly. The disease may remain confined to the lungs initially but has the potential to spread to other parts of the body through the bloodstream or lymphatic system. Common symptoms include persistent cough, chest pain, shortness of breath, and coughing up blood. Lung cancer can develop over many years, often without noticeable symptoms in its early stages.

Breast Cancer – Breast cancer is a disease where cells in the breast tissue begin to grow abnormally and form a tumor. The cancer typically starts in the milk ducts or the glands that produce milk, but can also begin in other breast tissues. As the abnormal cells multiply, they form a lump or mass that can be felt during examination or seen on imaging tests. The cancer cells can invade nearby tissues and may spread to lymph nodes under the arm or near the collarbone. If left unchecked, the cancer cells can travel through the bloodstream or lymphatic system to other parts of the body. The growth rate and behavior of breast cancer varies widely depending on the specific type and characteristics of the cancer cells.

Trial ID:
2025-521559-22-00
Trial Phase:
Therapeutic use (Phase IV)

Other Trials to Consider

  • A study to evaluate the use of [68Ga]BED003 for imaging colorectal, gastric, pancreatic, breast, and ovarian cancers.

    Recruiting

    2 1 1
    Investigated diseases:
    Italy The Netherlands
  • A study to test the safety and effectiveness of ONA-255 in patients with advanced cancer including breast cancer and gastric cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Spain